Your browser is no longer supported. Please, upgrade your browser.
Celyad Oncology SA
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-1.25%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-2.48%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-20.24%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.02 Perf Half Y-15.09%
Book/sh- P/B- EPS next Y- ROA- Target Price12.00 Perf Year-52.76%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range3.53 - 8.80 Perf YTD7.65%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-55.23% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low11.61% ATR0.18
Employees105 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)50.11 Volatility3.47% 4.24%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.01 Prev Close3.79
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume974.66K Price3.94
Recom- SMA202.23% SMA50-1.93% SMA200-16.83% Volume10,846 Change3.96%
Jul-05-19Reiterated H.C. Wainwright Buy $52 → $48
May-25-18Initiated Wells Fargo Outperform $44
Jan-20-22 09:40AM  
Jan-10-22 01:01AM  
Dec-31-21 01:50PM  
Dec-22-21 01:02AM  
Dec-17-21 04:05PM  
Dec-16-21 01:00AM  
Dec-15-21 01:01AM  
Dec-13-21 01:01AM  
Dec-08-21 04:05PM  
Dec-03-21 11:17AM  
Nov-12-21 07:00AM  
Nov-10-21 04:05PM  
Nov-04-21 09:01AM  
Nov-02-21 03:00AM  
Oct-29-21 04:05PM  
Oct-01-21 08:00AM  
Sep-01-21 01:00AM  
Aug-04-21 04:01PM  
Jul-30-21 01:00AM  
Jul-29-21 01:00AM  
Jul-20-21 04:01PM  
Jul-13-21 04:01PM  
Jul-07-21 04:01PM  
Jun-30-21 01:00AM  
Jun-11-21 02:59AM  
May-31-21 01:00AM  
May-26-21 01:00AM  
May-19-21 01:00AM  
May-13-21 06:52AM  
May-12-21 04:01PM  
May-06-21 04:01PM  
May-05-21 01:00AM  
May-04-21 01:00AM  
Apr-30-21 01:00AM  
Apr-19-21 01:00AM  
Apr-01-21 01:00AM  
Mar-31-21 01:00AM  
Mar-25-21 11:15AM  
Mar-24-21 04:01PM  
Mar-18-21 02:00AM  
Mar-01-21 04:01PM  
Feb-02-21 01:00AM  
Jan-20-21 04:05PM  
Jan-18-21 01:00AM  
Jan-11-21 04:01PM  
Jan-07-21 01:00AM  
Jan-05-21 01:00AM  
Dec-15-20 04:01PM  
Dec-07-20 01:00AM  
Dec-04-20 01:00AM  
Dec-01-20 04:01PM  
Nov-29-20 08:59AM  
Nov-10-20 04:01PM  
Nov-04-20 04:01PM  
Nov-02-20 04:01PM  
Sep-29-20 05:53PM  
Sep-23-20 04:01PM  
Sep-22-20 04:01PM  
Sep-14-20 01:00AM  
Aug-26-20 01:00AM  
Aug-06-20 04:01PM  
Aug-03-20 01:00AM  
Jul-15-20 10:34AM  
Jul-14-20 01:00AM  
Jun-10-20 01:00AM  
Jun-01-20 01:00AM  
May-27-20 09:34AM  
May-26-20 01:00AM  
May-25-20 12:00PM  
May-24-20 07:00AM  
May-07-20 01:00AM  
May-06-20 01:00AM  
Apr-30-20 01:00AM  
Apr-22-20 01:00AM  
Apr-20-20 09:06AM  
Mar-31-20 12:00PM  
Celyad Oncology, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of cancer. The company's lead drug product candidates include CYAD-01 and CYAD-02 autologous cell therapies, which are in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. It is also developing CYAD-101, an allogeneic cell therapy that is in Phase I clinical trial for the treatment of metastatic colorectal cancer; and CYAD-103, an allogeneic CAR-T product candidate that is in preclinical development for the treatment of solid tumors. The company's other preclinical candidates include CYAD-211, a CAR-T candidate targeting B-cell maturation antigen for the treatment of multiple myeloma; CYAD-221, a CAR-T candidate targeting CD19 for the treatment of B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting NKG2D and an undisclosed membrane protein. Celyad Oncology has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad Oncology was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.